Back to Agenda
Session 4: Considerations on Increased Transparency, Data Privacy and Data Sharing
Session Chair(s)
Merete Joergensen, MBA, MSc
Clinical Disclosure and Transparency Expert, Former EFPIA, CREG Clinical Trials
Merete-J Consulting CVR: 34920818, Denmark
During the Covid-19 pandemic focus has been to provide transparency both from the regulatory side and from industry trial sponsors to provide insights into the regulatory decision process, the trial results backing the decisions, and also to provide access to clinical trial data and results. This session will bring forward the viewpoints and challenges from Regulators and Industry perspective, and provide some insight into the needs as seen from the independent researchers side.
Speaker(s)
Experience and Current Strategy for Exceptional Transparency During the Covid-19 Pandemic
Juan Garcia-Burgos, MD, PhD
European Medicines Agency, Netherlands
Head of Public and Stakeholders Engagement Department
BioNTech/Pfizer Experience On Increased Transparency Demands for Covid-19
Lora Killian, MBA
Pfizer Inc, United States
Clinical Trial Transparency and Disclosure Lead
User Perspective for Data Sharing
Christian Ohmann, PhD
Chair of the Independent Data Centre Certification Board of ECRIN ,ECRIN, Germany
Chair of the Network Committee of the European Infrastructure ECRIN-ERIC
Have an account?